
Glooma
Our goal is to develop a home medical screening device to detect Breast Cancer at an early stage, avoiding more aggressive treatments, mutilating surgeries or even death.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
investor | €0.0 | round | |
investor investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor investor investor | €0.0 | round | |
investor | €0.0 | round | |
* | €690k | Grant | |
Total Funding | 000k |
EUR | 2022 | 2023 | 2024 |
---|---|---|---|
Revenues | 0000 | 0000 | 0000 |
EBITDA | 0000 | 0000 | 0000 |
Profit | 0000 | 0000 | 0000 |
EV | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
CleoCare, formerly known as Glooma, is a Portuguese health-tech company that has developed the SenseGlove, a medical device for at-home breast self-examinations. The company's mission is to empower women to actively manage their health through accessible and innovative tools. The SenseGlove guides users through a three-minute breast exam, generating a report that is automatically saved for tracking and sharing with healthcare professionals. This allows for the monitoring of breast tissue and the early detection of potential abnormalities.
The company targets women who want to be proactive about their breast health. The business model appears to be direct-to-consumer, selling the SenseGlove device. CleoCare was co-founded by Francisco Nogueira and Frederico Stock and is a spin-off from the NOVA University of Lisbon. The company has gained recognition in the health-tech space, including winning an award for the "Greatest Potential for Transfer of Technological Value" and joining the Breast Cancer Early Detection Coalition.
Keywords: health-tech, medical device, breast health, early detection, at-home monitoring, women's health, self-examination, med-tech, diagnostics, preventative care